Evidence map›Paper›PMID 35708863›Full record

ArticleMolecular biology reports2022

Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis.

Milene Roldão de Souza, Marilesia Ferreira de Souza, Monyse de Nóbrega, Heloísa Lizotti Cilião, Mariana Bisarro Dos Reis, Paulo Emílio Fuganti, Ilce Mara de Syllos Cólus

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Milene Roldão de SouzaDepartment of General Biology, State University of Londrina, Londrina, Paraná, Brazil.ORCID http://orcid.org/0000-0002-8656-4071
Marilesia Ferreira de SouzaDepartment of General Biology, State University of Londrina, Londrina, Paraná, Brazil.ORCID http://orcid.org/0000-0002-1556-3178
Monyse de NóbregaDepartment of General Biology, State University of Londrina, Londrina, Paraná, Brazil.ORCID http://orcid.org/0000-0002-8646-2171
Heloísa Lizotti CiliãoDepartment of General Biology, State University of Londrina, Londrina, Paraná, Brazil.ORCID http://orcid.org/0000-0001-7602-7160
Mariana Bisarro Dos Reis *Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, CEP14780-400, Brazil.ORCID http://orcid.org/0000-0002-5809-4471
Paulo Emílio FugantiLondrina Cancer Hospital, Londrina, Paraná, CEP: 86015-520, Brazil.ORCID http://orcid.org/0000-0001-6428-1065
Ilce Mara de Syllos Cólus *Department of General Biology, State University of Londrina, Londrina, Paraná, Brazil. ilcecolus@gmail.com.ORCID http://orcid.org/0000-0001-9098-1698
Universidade Estadual de Londrina · BRHospital de Câncer de Barretos · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 308231/2017-1Coordenação de Aperfeiçoamento de Pessoal de Nível Superior Finance Code 001Coordenação de Aperfeiçoamento de Pessoal de Nível Superior master's degree scholarshipsCoordenação de Aperfeiçoamento de Pessoal de Nível Superior post-doctoral fellowshipFundação Araucária 185/2014
6 · The paper itself

Abstract

backgroundThere is an ongoing search for molecular markers that are specific, sensitive, and able to predict the stage of prostate cancer (PCa), which is the second most prevalent type of cancer in men worldwide. This study examined whether different single nucleotide polymorphisms (SNPs) were reliable markers of susceptibility to and prognosis of PCa in a sample of Brazilian patients. METHODS AND

resultsDNA samples were extracted from peripheral blood cells of 283 PCa patients and matched with samples from healthy controls. Single nucleotide polymorphisms (SNPs in four genes (BCL-2-rs2279115, CASP3-rs4647603, CASP9-rs1052571, and NKX3-1-rs11781886) were genotyped by real-time PCR using the TaqMan® probe. Odds Ratios with 95% confidence intervals were calculated for allelic and genotypic frequencies. The association between polymorphic variants, risk of developing PCa, and clinicopathological characteristics was analyzed by univariate and multivariate logistic regression analysis. SNPs in CASP3, CASP9, and NKX3-1 genes, either alone or in combination (BCL-2+NKX3-1 and CASP3+NKX3-1) were associated with the risk of developing PCa. Genotypes and tumor histopathological data indicated that the BCL-2, NKX3-1, and CASP3 allelic variants, either alone or combined in pairs, were associated with a poor prognosis of PCa.

conclusionsGenetic polymorphisms in CASP3, NKX3-1, and BCL-2 genes were associated with susceptibility to PCa. The SNPs in the three genes alone and the SNP in the BCL-2 gene combined with the other two genes were strongly associated with adverse outcomes in PCa patients and are promising candidates for molecular markers for PCa prognosis.

Indexed as

Genes, bcl-2Prostatic NeoplasmsCase-Control StudiesCaspase 3Caspase 9Genetic Predisposition to DiseaseHomeodomain ProteinsHumansMalePolymorphism, Single NucleotideProto-Oncogene Proteins c-bcl-2Transcription FactorsCASP3 protein, humanCASP9 protein, humanCaspase 3Caspase 9Homeodomain ProteinsNKX3-1 protein, humanProto-Oncogene Proteins c-bcl-2Transcription FactorsApoptosis genesPrognosisPSASNPTumor suppressor gene

Identifiers

PMID35708863
OpenAlexW4282971994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.